Why Is CELLDEX THERAPEUTICS (CLDX) Stock Down Today?
By the Top Tier Newswire AI Desk · September 22, 2026 at 1:30 PM ET · reviewed against 14 wire stories
CELLDEX THERAPEUTICS (CLDX) is down -9.94% in the latest session. Our newswire has captured 14 stories on CLDX across 10 sources in the last 36 hours, with AI sentiment reading bullish (avg 58/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why CLDX stock is down today
Celldex Therapeutics (CLDX) fell 9.94% to $34.13 in a volatile session marked by sharp intraday swings and mixed reactions to recent clinical data. The stock opened with a 10.8% gap up but quickly reversed course amid investor uncertainty over the safety profile of its late-stage drug candidate barzolvolimab. The decline reflects concerns raised by some analysts and media outlets about the risk-benefit balance of the drug, despite meeting primary and key secondary endpoints in two Phase 3 trials for chronic spontaneous urticaria.
What Happened
Celldex announced positive topline results from the EMBARQ-CSU1 and EMBARQ-CSU2 trials, showing barzolvolimab met its primary endpoint and all key secondary endpoints in patients with antihistamine-refractory chronic spontaneous urticaria. The company highlighted a nearly 54% complete response rate at 24 weeks. Despite these results, the stock fell sharply after reports and commentary raised safety concerns, including a Reuters headline noting that safety issues were clouding the drug’s trial success. H.C. Wainwright analysts called the Phase 3 results compelling and noted nearly 90% upside potential, while Stifel reiterated a Buy rating. However, the broader market reaction was cautious, with the stock dropping to a session low of $22.10 before stabilizing.
What The Data Shows
The stock opened at $42.00 but quickly declined to a session low of $22.10, the same level as its 52-week low. Volume reached 8.0 million shares, or 8.4 times the 3-month average. Over the past eight sessions, CLDX has fallen 8.1%, from $36.90 to $33.92. On September 22, the stock printed 22 fresh 52-week lows and four 52-week highs. The session also saw a wide intraday range, from $22.10 to $53.65, reflecting intense retail and institutional activity. H.C. Wainwright raised its price target to $64 from $42, and both Morgan Stanley and Barclays also raised their price targets to $46 and $53 respectively, maintaining Overweight ratings.
What To Watch
Investors should monitor Celldex’s progress toward its 2027 FDA submission for barzolvolimab. The company’s upcoming earnings report and regulatory developments will be key to assessing the drug’s commercial potential and investor sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CLDX · today's session (5-min) · -10.74% vs prior close · updated 6:54 PM ETAI sentiment, last 36h · averaged over 14 stories · 58/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
5h agoStocktwits NewsNEUTRAL 54Analyst
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
H.C. Wainwright called the Phase 3 results a “compelling” late-stage assessment of Barzolvolimab in a patient population with a significant unmet need.
6h agoThe FlyBEARISH 34General
Celldex falls -11.4%
6h agoThe FlyBULLISH 67Analyst
Celldex price target raised to $64 from $42 at H.C. Wainwright
7h agoMarketChameleonBULLISH 76Product/PR
Celldex Highlights Phase 3 Barzolvolimab Data With Complete Response Near 54% at 24 Weeks in CSU
September 22, 2026
Celldex reported positive topline Phase 3 results from EMBARQ-CSU1 and EMBARQ-CSU2, with barzolvolimab meeting the primary endpoint and all key secondary endpoints in antihistamine-refractory chronic spontaneous urticaria. Complete response (UAS7=0) reached as high as 54.0% at 24 weeks, with statistically significant benefits also shown in omalizumab-refractory patients and in angioedema resolution. The program continues to 52 weeks, and Celldex said a BLA submission is anticipated in 2027.
Stifel reiterates Celldex Therapeutics stock Buy rating after trial data
Stifel reiterates Celldex Therapeutics stock Buy rating after trial data
7h agoReutersBEARISH 38General
Celldex shares slip as safety concerns cloud skin drug trial win
9h agoInvestorsHubBULLISH 73Earnings
Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials
Celldex shares rise 8% as barzolvolimab meets primary and key secondary endpoints in two Phase 3 trials for chronic spontaneous urticaria.
10h agoSeeking AlphaBEARISH 34Product/PR
Celldex falls after late-stage trial data for hives therapy
Celldex (CLDX) stock sank after the company posted Phase 3 trial data for its hives therapy. Read more here.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →